

To: [redacted] <[redacted]@minvws.nl>; [redacted] <[redacted]@igj.nl>; [redacted] <[redacted]@igj.nl>; [redacted] <[redacted]@minvws.nl>; [redacted] <[redacted]@minvws.nl>; [redacted] <[redacted]@minvws.nl>; [redacted] <[redacted]@igj.nl>; [redacted] <[redacted]@igj.nl>; [redacted] <[redacted]@cbg-meb.nl>; [redacted] <[redacted]@rvm.nl>; [redacted] <[redacted]@cbg-meb.nl>

Cc: [redacted] <[redacted]@cbg-meb.nl>

From: [redacted]

Sent: Wed 12/30/2020 4:59:58 PM

Subject: FW: EMA press release on status of rolling review of AstraZeneca's COVID-19 vaccine

Received: Wed 12/30/2020 5:00:03 PM

[Press release. Update on rolling review of AstraZeneca's COVID-19 vaccine.docx](#)

Beste collega's,

Het bijgevoegde document is het EMA persbericht over de rolling review van het AstraZeneca/Oxford vaccin. Het bevat niet helemaal de spierballentaal die vanochtend nog werd voorgesteld tijdens de EMRN meeting, maar het is op zich geen verkeerd bericht. Er staat duidelijk in dat er nog aanvullende wetenschappelijke informatie nodig is voor een verantwoorde beoordeling en dat er daartoe vragen aan de firma zijn gesteld.

Het bericht gaat om 18.00 uur naar buiten.

Groeten,

[redacted]

Van: [redacted] <[redacted]@ema.europa.eu> Namens [redacted]

Verzonden: woensdag 30 december 2020 17:35

Aan: [redacted] <[redacted]@ema.europa.eu>

CC: De Verdiere Morgane <[redacted]@ema.europa.eu>; [redacted] <[redacted]@ema.europa.eu>; [redacted] <[redacted]@ema.europa.eu>; [redacted] <[redacted]@ema.europa.eu>; [redacted] <[redacted]@ema.europa.eu>; [redacted] <[redacted]@ema.europa.eu>; [redacted] <[redacted]@ema.europa.eu>

Onderwerp: EMA press release on status of rolling review of AstraZeneca's COVID-19 vaccine

Dear Colleagues,

Following the Lines to take sent earlier today regarding the emergency use approval (EUA) of AstraZeneca's COVID-19 in the United Kingdom, please find attached an EMA public statement updating on the status of EMA's current assessment.

This statement has been agreed at a meeting of ETF this afternoon to which CHMP also participated.

The communication will be published on EMA's website **today, Wednesday, 30 December 2020, at 18:00 hrs CET**. Please note there is an embargo until such time.

If you need further information, please do not hesitate to contact me.

Best regards,

[redacted]
[redacted]

European Medicines Agency
Domenico Scarlattilaan 6 | 1083 HS Amsterdam | The Netherlands
Telephone +31 (0) 20 717 7474
[redacted] <[redacted]@ema.europa.eu> | www.ema.europa.eu | For directions, see [How to find us](#)

Follow us:   



This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this e-mail, or any disclosure or copying of its contents, or any action taken

(or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately.

This message has been sent to Heads of Medicines Agencies – Human; European Commission; CHMP Chair, Members and Alternates; PRAC Chair, Members and Alternates; CMD(h) Chair, Members and Alternates; PDCO Chair, Members and Alternates and WGCP (Working Group of Communication Professionals).

Classified as confidential by the European Medicines Agency

This e-mail has been scanned for all known viruses by European Medicines Agency.
